

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A method of specifically activating cytotoxic T lymphocytes *in vivo*, wherein said cytotoxic T lymphocytes (CTLs) specifically target malignant cells that express a Her-2/Neu protein *in vivo*, the method comprising the step of immunizing an animal with the polypeptide of SEQ ID NO:10.

Claims 2-60 (canceled)

Claim 61 (new): The method of claim 1, wherein said polypeptide is incorporated into a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

Claim 62 (new): The method of claim 1, wherein said polypeptide is linked to a carrier.

Claim 63 (new): The method of claim 1, wherein said polypeptide is introduced into a mammal as a homopolymer.

Claim 64 (new): The method of claim 1, further comprising the step of administering a second component to said animal, wherein said second component primes said CTLs for activation.

Claim 65 (new): The method of claim 64, wherein the second component comprises tripalmitoyl-S-glycerylcysteinyl-seryl-serine

(P<sub>3</sub>CSS).

Claim 66 (new): The method of claim 1, wherein the immunizing step further comprises co-administering a second component that primes said CTLs for activation.

Claim 67 (new): The method of claim 66, wherein the second component comprises tripalmitoyl-S-glycerylcysteinyl-seryl-serine (P<sub>3</sub>CSS).

Claim 68 (new): The method of claim 1, further comprising the step of administering a second polypeptide to said animal.

Claim 69 (new): The method of claim 68, wherein the second polypeptide comprises TPPAYRPPNAPIL (SEQ ID NO:9).

Claim 70 (new): The method of claim 1, wherein the immunizing step further comprises co-administering a second polypeptide to said animal.

Claim 71 (new): The method of claim 70, wherein the second polypeptide comprises TPPAYRPPNAPIL (SEQ ID NO:9).